Form 4: Bausch + Lomb Director Receives Annual Equity Grant of 20,338 Restricted Share Units

Bausch + Lomb Corporation's Director, Andrew C. Von Eschenbach, was granted 20,338 restricted share units as part of the company's annual non-employee director compensation plan.

Summary

• Andrew C. Von Eschenbach, a Director of Bausch + Lomb Corporation (BLCO), acquired 20,338 common shares on May 27, 2025.
• This acquisition was a grant of Restricted Share Units (RSUs) with a transaction price of $0 per share, indicating it was compensation rather than a purchase.
• The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• Following this transaction, Mr. Von Eschenbach's direct beneficial ownership of common shares increased to 62,086.
• The granted RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The document reports a routine and expected annual equity grant to a director, which is a positive sign of standard corporate governance and aligns the director's interests with long-term shareholder value. It does not indicate any negative or unexpected events.

Positives

• The grant of Restricted Share Units (RSUs) to a non-employee director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This transaction is part of a standard, pre-approved compensation plan (2022 Omnibus Incentive Plan), indicating routine and transparent corporate governance practices.
• Equity-based compensation helps retain experienced directors by providing a long-term incentive for their continued service and contribution to the company's success.

Future Outlook

The granted Restricted Share Units are scheduled to vest immediately prior to the next annual meeting of shareholders, which will result in the conversion of these units into common shares at that future date.

Industry Context

This Form 4 filing details a routine equity grant to a non-employee director, a common practice across publicly traded companies, particularly in the healthcare and pharmaceutical sectors like Bausch + Lomb. Such grants are standard components of director compensation packages, designed to align the interests of the board with long-term shareholder value and incentivize sustained commitment.

Comparison to Industry Standards

• The practice of granting Restricted Share Units (RSUs) to non-employee directors is a widely adopted compensation strategy across various industries, including healthcare and pharmaceuticals, exemplified by companies such as Johnson & Johnson (JNJ) and Abbott Laboratories (ABT).
• The Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, under which these RSUs were granted, is a typical framework for equity-based compensation, comparable to incentive plans at other large-cap pharmaceutical and medical device companies.
• The vesting schedule, tied to the next annual meeting of shareholders, is a common and accepted approach for annual director equity grants, ensuring continued service and alignment through the company's fiscal and governance cycle.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially leading to decisions that enhance shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The granted Restricted Share Units are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares of Bausch + Lomb Corporation.

Key Dates

Recommendation

Keywords

Bausch + Lomb, BLCO, Form 4, Insider Transaction, Restricted Share Units, RSU, Director Compensation, Equity Grant, Share Ownership, Corporate Governance